TSC BioVenture Management

Jessie J. Hsu serves as Managing Director and leads investment decisions for TSC BioVenture Management. She oversees the firm's pipeline in early-stage biotech and pharmaceutical investments, drawing on a network that spans Taiwan, the US, and mainland China. Her background includes direct operational and financial experience in the life-sciences sector.

The firm focuses on early-stage through late-stage venture, including seed, start-up, and expansion rounds, per its structured investment approach. It often participates in Series A and B rounds for biotech platforms and therapeutic assets, occasionally supporting companies through clinical inflection points. The stage agnosticism within venture allows flexibility for capital-intensive drug development timelines.

TSC BioVenture Management engages primarily in direct venture investment into private life-science companies, rather than operating as a fund-of-funds. The firm has historically co-invested alongside other specialist healthcare venture funds in syndicated rounds. It does not publicly market separate commingled funds to external allocators as a GP, operating with a mandate tied directly to its own capital base.

The firm represents one of the few Taiwan-headquartered venture platforms specifically dedicated to life sciences, a departure from the island's dominant electronics and semiconductor venture ecosystem. TSC BioVenture channels Taiwanese institutional and private wealth into biotechnology opportunities abroad, particularly in US-based drug development companies. Its existence reflects a structural diversification of cross-border capital flows from Taiwan's technology-generated wealth into healthcare innovation.

TSC BioVenture concentrates on biopharmaceuticals, medical devices, and digital health, with no public record of investment in healthcare services, payer models, or generics manufacturing. The firm appears to avoid capital-intensive large-molecule manufacturing plays and pure-play health IT without a clear therapeutic or diagnostic component. It has not disclosed positions in consumer health or wellness platforms.

The firm actively co-invests alongside specialist healthcare venture investors, as evidenced by its syndicated participation in rounds with firms such as Qiming Venture Partners. It typically enters as a minority investor in consortium-built financings for biotech companies with cross-border operational footprints. There is no public evidence of TSC leading rounds independently at scale.